RecruitingPhase 4

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests a single-layer patch made from donated placenta tissue, along with usual care, for diabetic foot sores that have not healed. It is for adults who received only usual care in the CAMPX trial and whose study sore was not fully closed after 12 weeks.

A multicenter, prospective, controlled clinical trial evaluating the efficacy of a single layer placental-based allograft and standard of care in the management of nonhealing diabetic foot ulcers.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be at least 18 years old.
  • Have type 1 or type 2 diabetes.
  • Have been in the usual-care-only group in the CAMPX trial, with a study sore that was not fully closed after 12 weeks.
  • If you have more than one sore, use the same study sore treated in CAMPX.
  • Agree to use the prescribed method to keep pressure off the sore throughout the study.
  • Agree to attend weekly study visits.
  • Be willing and able to take part in the informed consent process to decide whether to join.

Who can't join

  • Did not join CAMPX, were not assigned to its usual-care-only group, or had a study sore that fully closed; or the sore is not caused by diabetes.
  • Have an infected study sore, a skin infection around it, or a bone infection affecting it; have exposed tendon or bone; or have an infection anywhere that needs antibiotics that work throughout the body.
  • Take drugs that weaken the immune system, including more than 10 mg of prednisone daily or an equal dose of a similar steroid; take cell-killing cancer drugs or other drugs the study doctor thinks may slow healing; or used steroid cream on the sore within one month before screening.
  • Have a foot shape change from a past partial amputation that prevents keeping pressure off the sore; or have Charcot foot, a condition that damages foot bones and joints, that prevents this.
  • Have an HbA1c (a measure of blood sugar over time) of 12% or higher within three months before screening, or kidney failure needing dialysis.
  • Are pregnant or thinking about becoming pregnant within the next six months.
  • Are expected to live less than six months, or have a physical or mental health condition the study doctor thinks may interfere with study checks.
  • Have a score below 17 on the Mini Nutritional Assessment, a test for poor nutrition.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * The potential subject must be at least 18 years of age or older. * The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus. * If the potential subject has two or more ulcers, the target ulcer must be the same ulcer treated in the CAMPX study. * The potential subject must consent to using the prescribed offloading method for the duration of the study. * The potential subject must agree to attend the weekly study visits required by the protocol. * The potential subject must be willing and able to participate in the informed consent process. * The potential subject must have participated in the CAMPX trial in the SOC only arm and NOT achieved complete closure by the 12-week endpoint. Exclusion Criteria: * The potential subject is known to have a life expectancy of \< 6 months. * The potential subject's target ulcer is not secondary to diabetes. * The target ulcer is infected or there is cellulitis in the surrounding skin. * The target ulcer exposes tendon or bone. * There is evidence of osteomyelitis complicating the target ulcer. * There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy. * The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics). * The potential subject has applied topical steroids to the ulcer surface within one month of initial screening. * The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer. * The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit. * The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer. * The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months. * The potential subject has end stage renal disease requiring dialysis. * The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments. * The potential subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment. * The potential subject did not participate in the CAMPX trial. * The potential subject participated in the CAMPX trial and was not randomized to the SOC only arm. * The potential subject participated in the CAMPX trial and achieved complete closure.

Study sites (1)

FL